Literature DB >> 8274607

Pneumocystis carinii pneumonia in patients without AIDS.

K A Sepkowitz1.   

Abstract

In the 1980s, tens of thousands of cases of Pneumocystis carinii pneumonia (PCP) occurred in persons with AIDS, making it the most common opportunistic infection encountered in this patient population. Thus, the presentation and clinical course of PCP became well-known to many physicians. Overshadowed by this epidemic was the continued occurrence of PCP in persons not infected with the human immunodeficiency virus, most notably those receiving immunosuppressive therapy for neoplastic disease or other indications. A review from Memorial Sloan-Kettering Cancer Center has demonstrated that, in addition to those patients previously defined as at risk--those with acute lymphocytic leukemia or allogeneic bone marrow transplantation--patients receiving corticosteroid therapy for a primary or metastatic brain neoplasm are at risk for PCP and should receive prophylaxis. Among patients with neoplastic disease, the disease may be more fulminant and the mortality rate higher--approaching 50% in most series. Wider use of prophylaxis should decrease the frequency of this disease, while prompt initiation of therapy in patients with a compatible syndrome should help to lower mortality rates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274607     DOI: 10.1093/clinids/17.supplement_2.s416

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

Review 1.  Pneumocystis.

Authors:  Francis Gigliotti; Andrew H Limper; Terry Wright
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

3.  Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia.

Authors:  T W Wright; F Gigliotti; J N Finkelstein; J T McBride; C L An; A G Harmsen
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Pneumocystis jiroveci Pneumonia in an Atypical Host.

Authors:  Raquel E Reinbolt; Shadia Alam; Rachel Layman; Charles Shapiro; Maryam Lustberg
Journal:  Clin Breast Cancer       Date:  2011-12-01       Impact factor: 3.225

5.  Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients.

Authors:  H A Torres; R F Chemaly; R Storey; E A Aguilera; G M Nogueras; A Safdar; K V I Rolston; I I Raad; D P Kontoyiannis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

Review 6.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Typing of Pneumocystis carinii strains with type-specific oligonucleotide probes derived from nucleotide sequences of internal transcribed spacers of rRNA genes.

Authors:  J J Lu; M S Bartlett; J W Smith; C H Lee
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

8.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Authors:  Katrien Lagrou; Sharon Chen; Henry Masur; Claudio Viscoli; Catherine F Decker; Livio Pagano; Andreas H Groll
Journal:  Clin Infect Dis       Date:  2021-03-12       Impact factor: 9.079

9.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis.

Authors:  Yuqiong Wang; Xiaoyi Zhou; Maidinuer Saimi; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan
Journal:  Front Public Health       Date:  2021-06-16

Review 10.  Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Rheumatology (Oxford)       Date:  2012-09-22       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.